Navigation Links
CHMP Adopts Negative Opinion for ZEFTERA(TM)
Date:2/19/2010

BEERSE, Belgium, February 19, 2010 /PRNewswire-FirstCall/ --

- Cilag GmbH International to Terminate Collaboration

Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a negative opinion on its Marketing Authorisation Application (MAA) for the antibiotic ZEFTERA(TM) (ceftobiprole medocaril), for the treatment of complicated skin and soft tissue infections.

Cilag GmbH International has given Basilea Pharmaceutica Ltd. notice of termination of the worldwide License , Development and Co-Promotion Agreement between the parties. The compound, including pending applications and in-market products, will be transitioned back to Basilea under the terms of the License Agreement.

Janssen-Cilag International NV and Cilag GmbH International are Johnson & Johnson companies.

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Janssen-Cilag International NV and Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Neither Janssen-Cilag International NV nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.

For further information, please contact: Media: Karen Manson - Office: +44-1737-644-690or Investor Relations: Stan Panasewicz - Office: +1-732-524-2524

SOURCE Janssen-Cilag International NV

Back to top
'/>"/>
SOURCE Janssen-Cilag International NV
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotech, Inc. Adopts Stockholder Rights Plan
2. The Medical College of Wisconsin Adopts Quantros Event Manager(TM) and Claims Manager(TM) for Comprehensive Malpractice Litigation Management
3. Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media
4. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
5. SAFC Adopts Targeted Approach to Reach Pre-Registration
6. BMP Sunstone Adopts Voluntary Executive Compensation Restrictions in 2008 and 2009
7. Gowlings Adopts RFID and Unifies Practice Management
8. European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia
9. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
10. Informed Medical Communications Adopts Newly Enhanced Compliance Policy
11. Atom Medical Adopts Masimo Rainbow SET Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... Each year, Crain’s Detroit Business News ranks ... that evaluates the patent estate of a company, its impact and significance, and the ... leading the way in technologies that transform energy sources such as low dose X-ray ...
(Date:1/12/2017)... Jan. 12, 2017   Protein Sciences Corporation ... of Flublok Influenza Vaccine ®, announced today ... had good safety results and induced strong neutralizing ... The product is expected to advance into human ... addition, the Institute of Technology in Immunobiologicals of ...
(Date:1/11/2017)... ... January 11, 2017 , ... Ovation Fertility™ Genetics now offers ... genetic screening (PGS). , “Our genetics and IVF teams are recognized experts in ... Director Amy Jones, M.S., ELD (ABB) , who has worked with or ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... observed in clinical settings, it is becoming increasingly clear that the evolution and ... culture-based methods, the standard in the study of clinical resistance, has vastly underestimated ...
Breaking Biology Technology:
(Date:12/22/2016)... , December 22, 2016 SuperCom (NASDAQ: ... secure solutions for the e-Government, Public Safety, HealthCare, and Finance sectors ... SuperCom, has been selected to implement and deploy a community-based supportive ... Northern California , further expanding its presence in the ... This new ...
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions ... Identity management products and solutions and a cutting-edge ... today that it is offering seamless, integrated solutions ... security entrance products. The solutions provide IdentyTech,s customers ... secure their facilities from crime and theft. ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
Breaking Biology News(10 mins):